Skip to content

Arbutus Biopharma Corporation ABUS Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1

Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 at other companies

Beam Therapeutics logo
Beam TherapeuticsBEAM
-$514K-2,004%

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$871.14M+32.6%
Enterprise value$848.07M+36.6%
P/E5.4×
P/S4.6×-98.0×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Arbutus Biopharma Corporation’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's business combination contingent consideration arrangements change in amount of contingent consideration liability1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
Arbutus Biopharma Corporation (ABUS) reported business combination contingent consideration arrangements change in amount of contingent consideration liability1 of -$457.5K in Q4 2025.
How has Arbutus Biopharma Corporation's business combination contingent consideration arrangements change in amount of contingent consideration liability1 changed year-over-year?
Arbutus Biopharma Corporation's business combination contingent consideration arrangements change in amount of contingent consideration liability1 decreased by 169.7% year-over-year, from $656.25K to -$457.5K.
What is the long-term trend for Arbutus Biopharma Corporation's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's business combination contingent consideration arrangements change in amount of contingent consideration liability1 has grown at a -0.6% compound annual growth rate (CAGR), from $1.87M to -$1.83M.
What does business combination contingent consideration arrangements change in amount of contingent consideration liability1 mean?
This metric represents the periodic adjustment to the fair value of liabilities arising from contingent consideration arrangements in business combinations. It reflects changes in the estimated probability or timing of future payments owed to sellers based on the achievement of specific performance milestones or financial targets. Investors monitor this to assess the impact of acquisition-related earn-outs on the company's net income and to gauge the underlying performance of acquired assets.